CD274 and neoplasm: SL-279252, a bi-functional fusion protein that binds simultaneously to PD-L1 and OX-40 stimulating anti-tumor T-cell activity, is currently being tested in a clinical trial in several types of solid cancer, including CSCC (NCT03894618).